hims and hers tirzepatide The FDA announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company & to yank its new compounded semaglutide (Wegovy) weight-loss pill from the FDA Takes Aim at Hims

Hold shift to jump forward or backward

Patients and clinicians alike are weighing the proven benefits of semaglutide against potential risks like abdominal pain, bile flow problems, or even pancreatitis

By injecting in the evening, the worst symptoms occur during sleep rather than interrupting daytime activities

Neurotransmitter modulation by the gut microbiota

Who is not a good fit for this program

Tirzepatide received FDA approval as Mounjaro in May 2022 for type 2 diabetes mellitus and as Zepbound in November 2023 for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity